EWTX Edgewise Therapeutics, Inc.
Price Chart
Executive Summary
Edgewise Therapeutics announced an asset purchase agreement to sell its neuromuscular program, including the sevasemten compound, to Servier for $1.55 billion in upfront cash, plus up to $1.1 billion in regulatory and commercial milestones. The transaction transforms Edgewise into a cardiovascular-focused company, with proceeds expected to fully fund EDG-7500 development through potential approval. The deal is expected to close in Q3 2026, subject to HSR clearance and customary conditions.
Key Financial Metrics
Actionable Insight
The $1.55B upfront cash infusion dramatically de-risks Edgewise's cardiovascular pipeline and provides a clean balance sheet. The stock should re-rate on the cash value alone — the implied cash per share is substantial relative to the current market cap. Key catalysts ahead: CIRRUS-HCM Part D data (Q2 2026) and GRAND CANYON Becker data (Q4 2026) which triggers a $200M milestone. Monitor HSR clearance timeline.
Key Facts
- Edgewise sells sevasemten and related neuromuscular assets to Servier for $1.55 billion upfront cash.
- Potential milestone payments up to $1.1 billion: $200M or $100M for Becker approval, $600M for Duchenne approval, $300M for sales milestone.
- Proceeds fully fund EDG-7500 development through potential approval and strengthen the balance sheet.
- Edgewise becomes a pure-play cardiovascular company focused on EDG-7500 (Phase 2 HCM), EDG-15400 (Phase 1 HFpEF), and EDG-003 (preclinical).
- Transaction approved by both boards; expected to close in Q3 2026 subject to HSR clearance.
- Edgewise to report 12-week CIRRUS-HCM Part D data in Q2 2026.
Financial Impact
$1.55 billion upfront cash plus up to $1.1 billion in milestones, versus a pre-announcement market cap of $3.7B (upfront alone represents ~42% of market cap in cash).
Risk Factors
- HSR regulatory delay or unexpected antitrust issues could push closing beyond Q3 2026.
- Milestone payments are contingent on FDA approvals and commercial sales — not guaranteed.
- Post-transaction, Edgewise's valuation depends entirely on early-stage cardiovascular pipeline (EDG-7500, EDG-15400) with no approved products.
- CIRRUS-HCM Phase 2 data risk — if 12-week results are weak, the remaining pipeline thesis is undermined.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249951 |
| Document: d24037dex991.htm | 0001193125-26-249951 |
| Document: 0001193125-26-249951-index-headers.html | 0001193125-26-249951 |
| Document: 0001193125-26-249951-index.html | 0001193125-26-249951 |
| Document: 0001193125-26-249951.txt | 0001193125-26-249951 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
11d ago
|
8-K
| $40.26 $35.59 | ▼ −11.60% | ▼ −8.85% | $34.83 (−13.49%) |
|
May 7, 2026
5w ago
|
8-K
| $35.58 $33.76 | ▼ −5.12% | ▼ −6.62% | $34.83 (−2.11%) |
|
Apr 23, 2026
7w ago
|
DEFA14A
| $31.58 $30.96 | ▼ −1.96% | ▼ −2.87% | $34.83 (+10.29%) |
|
Mar 27, 2026
11w ago
|
144
| $30.28 $32.50 | ▲ +7.33% | ▲ +3.03% | $34.83 (+15.03%) |
|
Feb 26, 2026
15w ago
|
8-K
| $29.66 $28.39 | ▼ −4.28% | ▼ −3.15% | $34.83 (+17.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access